PTC Therapeutics/PTCT

$30.75

-3.76%
-
1D1W1MYTD1YMAX

About PTC Therapeutics

PTC Therapeutics, Inc. is a science-driven, global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Its portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It also offers Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, and Evrysdi, a treatment for spinal muscular atrophy (SMA). Its splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease (HD).

Ticker

PTCT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Matthew Klein

Employees

988

Headquarters

South plainfield, United States

PTC Therapeutics Metrics

BasicAdvanced
$2.45B
Market cap
-
P/E ratio
-$8.37
EPS
0.66
Beta
-
Dividend rate

What the Analysts think about PTC Therapeutics

Analyst Ratings

Majority rating from 14 analysts.
Hold

Price Targets

Average projection from 11 analysts.
14.57% downside
High $45.00
Low $15.00
$30.75
Current price
$26.27
Average price target

PTC Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-50.71% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$307M
56.23%
Net income
$-155.7M
17.16%
Profit margin
-50.71%
-25.02%

PTC Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 515.71%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.88
-$2.66
-$1.76
-$2.06
-
Expected
-$1.30
-$1.24
-$1.17
$0.50
-$1.39
Surprise
44.78%
113.71%
50.36%
-515.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell PTC Therapeutics stock

Buy or sell PTC Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing